María Río, Vice President and Managing Director Gilead Spainand its managing director, Cristóbal Belda Carlos III Institute of Health (ISCIII)signed the cooperation agreement for the meeting this Thursday. IX Gilead Fellowships for Biomedical Research, a benchmarking event in the healthcare industry Spanish this year 950 thousand euro donation.
The main innovation of this edition is, in addition to projects for HIV, viral hepatitis (C and Delta), hemato-oncology, covid-19 and invasive fungal infection, Top research articles on Medical Oncology. This will rely on the collaboration of the major scientific communities/collaborative groups in the therapeutic fields involved in this call.
in his words María Río, Vice President and Managing Director of Gilead, Spain“At Gilead we are proud of our contribution to the promotion of Research in Spain. The Gilead Biomedical Research Fellowships is one of our most beloved initiatives and we are delighted to be able to celebrate its Ninth Edition this year. We take this opportunity to include Oncology in the areas to which our Fellowships are directed, and we trust this decision will be an important support for our researchers to generate relevant knowledge in this specialty, as has been achieved in other areas in previous editions. ”
Cristóbal Belda, director of the Carlos III Institute of Healthstated: “ISCIII will always support and encourage these two-pronged initiatives that support biomedical and health research. The collaboration with these fellowships is a new example of the Institute’s commitment to science and knowledge production at the service of citizens and patients”.
At the service of biomedical research
The Gilead Biomedical Research Fellowships were established in 2013 to: promoting biomedical research in clinical care centers With the investment of 7.5 million Euros and the number of approved projects, Spain has become a touchstone in the health sector. During this period, a total of 535 research projects were presented, of which 145 were selected, corresponding to 13 autonomous communities and 47 care centers. ISCIII’s collaboration ensures that the research project review process complies with the principles of transparency, objectivity and independence necessary for the correct selection of projects to be funded.
Attempts to apply for Gilead Grants for Biomedical Research Must be formulated in English on the web by 12 July www.becasgileadinvestigacion.es. Each principal investigator may submit only one research project proposal, and a maximum of two projects will be allowed per treatment area and health center to which the principal investigator is affiliated. An independent evaluation committee of international evaluators appointed by the Carlos III Institute of Health will then be tasked with reviewing and prioritizing the projects.